» Articles » PMID: 23871243

Cell-to-cell Heterogeneity in Lipid Droplets Suggests a Mechanism to Reduce Lipotoxicity

Abstract

Lipid droplets (LDs) are dynamic organelles that collect, store, and supply lipids [1]. LDs have a central role in the exchange of lipids occurring between the cell and the environment and provide cells with substrates for energy metabolism, membrane synthesis, and production of lipid-derived molecules such as lipoproteins or hormones. However, lipid-derived metabolites also cause progressive lipotoxicity [2], accumulation of reactive oxygen species (ROS), endoplasmic reticulum stress, mitochondrial malfunctioning, and cell death [2]. Intracellular accumulation of LDs is a hallmark of prevalent human diseases, including obesity, steatosis, diabetes, myopathies, and arteriosclerosis [3]. Indeed, nonalcoholic fatty liver disease is the most common cause of abnormal hepatic function among adults [4, 5]. Lipotoxicity gradually promotes cellular ballooning and disarray, megamitochondria, accumulation of Mallory's hyaline in hepatocytes, and inflammation, fibrosis, and cirrhosis in the liver. Here, using confocal microscopy, serial-block-face scanning electron microscopy, and flow cytometry, we show that LD accumulation is heterogeneous within a cell population and follows a positive skewed distribution. Lipid availability and fluctuations in biochemical networks controlling lipolysis, fatty acid oxidation, and protein synthesis contribute to cell-to-cell heterogeneity. Critically, this reversible variability generates a subpopulation of cells that effectively collect and store lipids. This high-lipid subpopulation accumulates more LDs and more ROS and reduces the risk of lipotoxicity to the population without impairing overall lipid homeostasis, since high-lipid cells can supply stored lipids to the other cells. In conclusion, we demonstrate fat storage compartmentalization within a cell population and propose that this is a protective social organization to reduce lipotoxicity.

Citing Articles

Coffee Compounds Protection Against Lipotoxicity Is Associated with Lipid Droplet Formation and Antioxidant Response in Primary Rat Hepatocytes.

Arroyave-Ospina J, Martinez M, Buist-Homan M, Palasantzas V, Arrese M, Moshage H Antioxidants (Basel). 2025; 14(2).

PMID: 40002362 PMC: 11851918. DOI: 10.3390/antiox14020175.


Physiological accumulation of lipid droplets in the newborn liver during breastfeeding is driven by TLR4 ligands.

da Silva Junior W, de Oliveira Costa K, Castro Oliveira H, Antunes M, Mafra K, Nakagaki B J Lipid Res. 2025; 66(2):100744.

PMID: 39814317 PMC: 11849619. DOI: 10.1016/j.jlr.2025.100744.


Lipid droplet formation induced by icaritin derivative IC2 promotes a combination strategy for cancer therapy.

Wu G, Ying L, Zhang Q, Xiong H, Wang J, Chen S Chin Med. 2024; 19(1):178.

PMID: 39725994 PMC: 11670343. DOI: 10.1186/s13020-024-01050-5.


Lipid droplet biogenesis in the ovary.

Ibayashi M, Tsukamoto S Reprod Med Biol. 2024; 23(1):e12618.

PMID: 39677329 PMC: 11646352. DOI: 10.1002/rmb2.12618.


S-acylation of ATGL is required for lipid droplet homoeostasis in hepatocytes.

Zheng Y, Chen J, Macwan V, Dixon C, Li X, Liu S Nat Metab. 2024; 6(8):1549-1565.

PMID: 39143266 DOI: 10.1038/s42255-024-01085-w.


References
1.
Wu J, Merlino G, Fausto N . Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A. 1994; 91(2):674-8. PMC: 43011. DOI: 10.1073/pnas.91.2.674. View

2.
Mak H . Lipid droplets as fat storage organelles in Caenorhabditis elegans: Thematic Review Series: Lipid Droplet Synthesis and Metabolism: from Yeast to Man. J Lipid Res. 2011; 53(1):28-33. PMC: 3243478. DOI: 10.1194/jlr.R021006. View

3.
Shahrezaei V, Swain P . The stochastic nature of biochemical networks. Curr Opin Biotechnol. 2008; 19(4):369-74. DOI: 10.1016/j.copbio.2008.06.011. View

4.
Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

5.
Browning J, Horton J . Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114(2):147-52. PMC: 449757. DOI: 10.1172/JCI22422. View